Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal
cells. This may be an effective treatment for hairy cell leukemia(HCL) that has not responded
to chemotherapy, surgery or radiation therapy.
PURPOSE: Phase I dose escalation study to determine the maximum tolerated dose of CAT-8015
immunotoxin in treating patients who have hairy cell leukemia (HCL) that has not responded to
treatment.